Absence of major fibrotic adverse events in hyperprolactinemic patients treated with cabergoline
European Journal of Endocrinology2010Vol. 162(4), pp. 667–675
Citations Over TimeTop 10% of 2010 papers
Melvin Lafeber, Aline M.E. Stades, Gerlof D. Valk, Maarten J. Cramer, F. Teding van Berkhout, Pierre Zelissen
Abstract
Cabergoline, typically dosed for the long-term treatment of hyperprolactinemia or acromegaly, appears not to be associated with an increased risk of fibrotic adverse events.
Related Papers
- → Update in Prolactinomas(2012)2 cited
- → Giant pubertal prolactinoma: Complete resolution following short term carbegoline treatment(2016)2 cited
- → Beat the giant: case of a giant prolactinoma during pregnancy on cabergoline(2018)2 cited
- → Pituitary abscess after cabergoline treatment of a prolactinoma in a 56 year old male: case report and review of the literature(2013)
- → A rapidly resolving prolactinoma with cabergoline treatment(2017)